PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Short Interest Update

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) was the target of a large decrease in short interest in February. As of February 27th, there was short interest totaling 1,232,783 shares, a decrease of 18.0% from the February 12th total of 1,503,564 shares. Based on an average daily trading volume, of 882,107 shares, the short-interest ratio is presently 1.4 days. Approximately 2.5% of the shares of the stock are short sold. Approximately 2.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 882,107 shares, the short-interest ratio is presently 1.4 days.

PMV Pharmaceuticals Stock Performance

Shares of PMV Pharmaceuticals stock remained flat at $1.56 during mid-day trading on Monday. 152,985 shares of the company were exchanged, compared to its average volume of 642,310. PMV Pharmaceuticals has a 1-year low of $0.81 and a 1-year high of $1.88. The company has a market capitalization of $83.19 million, a P/E ratio of -1.05 and a beta of 1.26. The company has a fifty day simple moving average of $1.23 and a 200-day simple moving average of $1.31.

PMV Pharmaceuticals (NASDAQ:PMVP) last released its quarterly earnings results on Friday, March 6th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.06. On average, equities research analysts expect that PMV Pharmaceuticals will post -1.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. BML Capital Management LLC increased its holdings in PMV Pharmaceuticals by 33.4% during the 2nd quarter. BML Capital Management LLC now owns 5,000,000 shares of the company’s stock valued at $5,300,000 after purchasing an additional 1,252,388 shares in the last quarter. Stonepine Capital Management LLC raised its position in PMV Pharmaceuticals by 34.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 845,968 shares of the company’s stock valued at $897,000 after purchasing an additional 215,785 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in PMV Pharmaceuticals in the third quarter worth $282,000. Bridgeway Capital Management LLC boosted its stake in PMV Pharmaceuticals by 115.5% in the third quarter. Bridgeway Capital Management LLC now owns 320,653 shares of the company’s stock worth $449,000 after purchasing an additional 171,853 shares in the last quarter. Finally, Tang Capital Management LLC grew its holdings in shares of PMV Pharmaceuticals by 3.2% during the fourth quarter. Tang Capital Management LLC now owns 4,940,000 shares of the company’s stock worth $6,175,000 after purchasing an additional 154,799 shares during the last quarter. 90.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PMV Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $5.00.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.